Please use this identifier to cite or link to this item:
https://doi.org/10.1097/01.TP.0000054682.53834.EA
DC Field | Value | |
---|---|---|
dc.title | Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transplant recipients: A preliminary experience | |
dc.contributor.author | Aw, M.M. | |
dc.contributor.author | Taylor, R.M. | |
dc.contributor.author | Verma, A. | |
dc.contributor.author | Parke, A. | |
dc.contributor.author | Baker, A.J. | |
dc.contributor.author | Hadzic, D. | |
dc.contributor.author | Muiesan, P. | |
dc.contributor.author | Rela, M. | |
dc.contributor.author | Heaton, N.D. | |
dc.contributor.author | Mieli-Vergani, G. | |
dc.contributor.author | Dhawan, A. | |
dc.date.accessioned | 2013-11-18T08:32:54Z | |
dc.date.available | 2013-11-18T08:32:54Z | |
dc.date.issued | 2003 | |
dc.identifier.citation | Aw, M.M., Taylor, R.M., Verma, A., Parke, A., Baker, A.J., Hadzic, D., Muiesan, P., Rela, M., Heaton, N.D., Mieli-Vergani, G., Dhawan, A. (2003). Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transplant recipients: A preliminary experience. Transplantation 75 (6) : 796-799. ScholarBank@NUS Repository. https://doi.org/10.1097/01.TP.0000054682.53834.EA | |
dc.identifier.issn | 00411337 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/48032 | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1097/01.TP.0000054682.53834.EA | |
dc.source | Scopus | |
dc.type | Conference Paper | |
dc.contributor.department | PAEDIATRICS | |
dc.description.doi | 10.1097/01.TP.0000054682.53834.EA | |
dc.description.sourcetitle | Transplantation | |
dc.description.volume | 75 | |
dc.description.issue | 6 | |
dc.description.page | 796-799 | |
dc.description.coden | TRPLA | |
dc.identifier.isiut | 000181814500012 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.